Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
12099 | 868 | 27.9 | 70% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | WALDENSTROMS MACROGLOBULINEMIA | Author keyword | 93 | 52% | 15% | 126 |
2 | WALDENSTROM MACROGLOBULINEMIA | Author keyword | 80 | 62% | 10% | 83 |
3 | BING WALDENSTROMS MACROGLOBULINEMIA | Address | 54 | 73% | 5% | 41 |
4 | LYMPHOPLASMACYTIC LYMPHOMA | Author keyword | 39 | 51% | 6% | 54 |
5 | BING NEEL SYNDROME | Author keyword | 21 | 85% | 1% | 11 |
6 | WALDENSTROMS MACROGLOBULINAEMIA | Author keyword | 14 | 48% | 2% | 21 |
7 | WALDENSTROM MACROGLOBULINAEMIA | Author keyword | 13 | 53% | 2% | 17 |
8 | BING PROGRAM WALDENSTROMS MACROGLOBULINEMIA | Address | 11 | 78% | 1% | 7 |
9 | MACROGLOBULINEMIA | Author keyword | 8 | 33% | 2% | 21 |
10 | MYD88 L265P | Author keyword | 8 | 75% | 1% | 6 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CONSENSUS PANEL RECOMMENDATIONS | 243 | 91% | 12% | 101 |
2 | 2ND INTERNATIONAL WORKSHOP | 184 | 86% | 11% | 93 |
3 | LYMPHOPLASMACYTIC LYMPHOMA WALDENSTROM MACROGLOBULINEMIA | 53 | 95% | 2% | 18 |
4 | WALDENSTROMS MACROGLOBULINEMIA | 22 | 23% | 10% | 84 |
5 | FLUDARABINE THERAPY | 21 | 51% | 3% | 30 |
6 | MYD88 L265P | 19 | 64% | 2% | 18 |
7 | 6Q DELETION | 18 | 89% | 1% | 8 |
8 | IGM MONOCLONAL GAMMOPATHY | 17 | 31% | 5% | 46 |
9 | L265P SOMATIC MUTATION | 16 | 58% | 2% | 19 |
10 | EXTENDED RITUXIMAB THERAPY | 15 | 82% | 1% | 9 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CLINICAL LYMPHOMA | 3 | 13% | 2% | 18 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia | 2003 | 327 | 30 | 83% |
How I treat Waldenstrom macroglobulinemia | 2009 | 64 | 66 | 76% |
Diagnosis and management of Waldenstrom's macroglobulinemia | 2005 | 102 | 88 | 73% |
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia | 2006 | 92 | 12 | 83% |
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia | 2003 | 104 | 14 | 100% |
Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia | 2009 | 53 | 11 | 73% |
Waldenstrom macroglobulinemia | 2007 | 78 | 97 | 72% |
Waldenstrom's macroglobulinemia: Clinical features, complications, and management | 2000 | 166 | 100 | 55% |
Waldenstrom Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management | 2012 | 24 | 74 | 80% |
Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus | 2014 | 6 | 47 | 77% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BING WALDENSTROMS MACROGLOBULINEMIA | 54 | 73% | 4.7% | 41 |
2 | BING PROGRAM WALDENSTROMS MACROGLOBULINEMIA | 11 | 78% | 0.8% | 7 |
3 | BING WALDENSTROM MACROGLOBULINEMIA | 6 | 80% | 0.5% | 4 |
4 | WALDENSTROMS MACROGLOBULINEMIA PROGRAM | 6 | 100% | 0.5% | 4 |
5 | HMDS | 4 | 25% | 1.6% | 14 |
6 | KIR WALDENSTROM MACROGLOBULINEMIA | 3 | 100% | 0.3% | 3 |
7 | GRECHY | 1 | 50% | 0.2% | 2 |
8 | SERV HEMATOL IMMUNOL CYTOGENET | 1 | 14% | 0.6% | 5 |
9 | ALLOGENE BMT PROGRAM | 1 | 50% | 0.1% | 1 |
10 | BIOSTAT BRANCHNIH | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000178999 | SCHNITZLER SYNDROME//SCHNITZLERS SYNDROME//NEUTROPHILIC URTICARIAL DERMATOSIS |
2 | 0.0000127558 | IMMUNOFIXATION ELECTROPHORESIS//FREE LIGHT CHAINS//SERUM FREE LIGHT CHAINS |
3 | 0.0000095435 | SPLENIC MARGINAL ZONE LYMPHOMA//NODAL MARGINAL ZONE LYMPHOMA//MONOCYTOID B CELL LYMPHOMA |
4 | 0.0000070959 | RICHTERS SYNDROME//RICHTER SYNDROME//COMPOSITE LYMPHOMA |
5 | 0.0000069073 | FLUDARABINE//CHRONIC LYMPHOCYTIC LEUKEMIA//CLADRIBINE |
6 | 0.0000063412 | PLASMA CELL LEUKEMIA//PRIMARY PLASMA CELL LEUKEMIA//MMSET |
7 | 0.0000054774 | MU HEAVY CHAIN DISEASE//HEAVY CHAIN DISEASE//GAMMA HEAVY CHAIN DISEASE |
8 | 0.0000054714 | MULTIFOCAL MOTOR NEUROPATHY//CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY//CIDP |
9 | 0.0000050449 | LIGHT CHAIN DEPOSITION DISEASE//CRYSTAL STORING HISTIOCYTOSIS//HEAVY CHAIN DEPOSITION DISEASE |
10 | 0.0000045691 | PLASMACYTOMA//EXTRAMEDULLARY PLASMACYTOMA//SOLITARY PLASMACYTOMA |